Haben Ghermazien

Statistics

Publications

Citations

1.3K

H-Index

Active since

2007

Affiliations

Technion – Israel Institute of Technology(Current)

Gilead Sciences (United States)

Haben Ghermazien is an author at Technion – Israel Institute of Technology specializing in oncology, allosteric inhibition, and lysyl oxidase inhibition.

Publications per year

2007–2016

Publications

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

Vivian Barry-Hamilton, Rhyannon Spangler, Derek Marshall et al. · Nature Medicine · 2010 · 855 citations

Life Sciences, Biochemistry, Cell Biology +13

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

Derek Marshall, Susan K. Lyman, Scott McCauley et al. · PLoS ONE · 2015 · 195 citations · Full text

Medicine, Oncology, Pharmacology +17

Developmental Switch in the Contribution of Presynaptic and Postsynaptic NMDA Receptors to Long-Term Depression

Rebekah Corlew, Yun Wang, Haben Ghermazien et al. · Journal of Neuroscience · 2007 · 175 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours

Shelly Zaffryar‐Eilot, Derek Marshall, Tali Voloshin et al. · Carcinogenesis · 2013 · 91 citations · Full text

Medicine, Oncology, Pharmacology +14

Abstract 1476: A therapeutic antibody that inhibits CD73 activity by dual mechanisms

Bryan C. Barnhart, Emanuela Sega, Aaron P. Yamniuk et al. · Cancer Research · 2016 · 12 citations

Pharmacy, Immunology, Oncology +15

1–5 of 5